Neuromelanin, neurotransmitter status and brainstem location determine the differential vulnerability of catecholaminergic neurons to mitochondrial DNA deletions

Molecular Brain

Volumn 4, Issue 1, 2011, Pages

  Elstner, Matthias ^a,b   Müller, Sarina K ^a   Leidolt, Lars ^a   Laub, Christoph ^a,b   Krieg, Lena ^a   Schlaudraff, Falk ^c   Liss, Birgit ^c   Morris, Chris ^d   Turnbull, Douglass M ^d   Masliah, Eliezer ^e   Prokisch, Holger ^f,g   Klopstock, Thomas ^a,b   Bender, Andreas ^a,h  

^a LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d NEWCASTLE UNIVERSITY   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

^f TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^g INSTITUTE OF EPIDEMIOLOGY   (Germany)

^h NONE   (Germany)

Author keywords

aging; catecholaminergic neurons; laser microdissection; mitochondrial DNA; neurodegeneration; Parkinson disease; single neuron analysis

Indexed keywords

MITOCHONDRIAL DNA; NEUROMELANIN; NEUROTRANSMITTER; AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; MELANIN;

AGING; ARTICLE; BRAIN STEM; CATECHOLAMINE METABOLISM; CATECHOLAMINE NERVE CELL; CELL POPULATION; CELL SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; DNA DAMAGE; DOPAMINERGIC NERVE CELL; GENE DELETION; HUMAN; HUMAN CELL; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; LOCUS CERULEUS; NERVE CELL DEGENERATION; NUCLEUS ACCUMBENS; PARKINSON DISEASE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; REAL TIME POLYMERASE CHAIN REACTION; SUBSTANTIA NIGRA PARS COMPACTA; VENTRAL TEGMENTUM; ADRENERGIC NERVE CELL; AGED; CHOLINERGIC NERVE CELL; CYTOLOGY; GENETICS; HISTOLOGY; METABOLISM; MIDDLE AGED; PATHOLOGY; PHYSIOLOGY;

ADRENERGIC NEURONS; AGED; AGED, 80 AND OVER; BRAIN STEM; CHOLINERGIC NEURONS; DNA DAMAGE; DNA, MITOCHONDRIAL; DOPAMINERGIC NEURONS; GENE DELETION; HUMANS; MELANINS; MIDDLE AGED; NEUROTRANSMITTER AGENTS; PARKINSON DISEASE;

EID: 83755173699     PISSN: None     EISSN: 17566606     Source Type: Journal    
DOI: 10.1186/1756-6606-4-43     Document Type: Article

References (43)

1. Mitochondrial contribution to Parkinson's disease pathogenesis. Schapira AH, Gegg M, Parkinsons Dis 2011 2011 159160 21687805
2. The biologic clock: the mitochondria? Harman D, J Am Geriatr Soc 1972 20 145 147 5016631
3. The origins of oxidant stress in Parkinson's disease and therapeutic strategies. Surmeier DJ, Guzman JN, Sanchez-Padilla J, Goldberg JA, Antioxid Redox Signal 2011 14 1289 1301 10.1089/ars.2010.3521 20712409
4. Mitochondrial DNA deletions in human brain: regional variability and increase with advanced age. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, Wallace DC, Nat Genet 1992 2 324 329 10.1038/ng1292-324 1303288
5. A pattern of accumulation of a somatic deletion of mitochondrial DNA in aging human tissues. Cortopassi GA, Shibata D, Soong NW, Arnheim N, Proc Natl Acad Sci USA 1992 89 7370 7374 10.1073/pnas.89.16.7370 1502147
6. High levels of mitochondrial DNA deletions in substantia nigra neurons in aging and Parkinson disease. Bender A, Krishnan KJ, Morris CM, Taylor GA, Reeve AK, Perry RH, Jaros E, Hersheson JS, Betts J, Klopstock T, Taylor RW, Turnbull DM, Nat Genet 2006 38 515 517 10.1038/ng1769 16604074
7. Mitochondrial DNA deletions are abundant and cause functional impairment in aged human substantia nigra neurons. Kraytsberg Y, Kudryavtseva E, McKee AC, Geula C, Kowall NW, Khrapko K, Nat Genet 2006 38 518 520 10.1038/ng1778 16604072
8. Dopaminergic midbrain neurons are the prime target for mitochondrial DNA deletions. Bender A, Schwarzkopf RM, McMillan A, Krishnan KJ, Rieder G, Neumann M, Elstner M, Turnbull DM, Klopstock T, J Neurol 2008 255 1231 1235 10.1007/s00415-008-0892-9 18604467
9. Mitochondrial DNA deletions cause the biochemical defect observed in Alzheimer's disease. Krishnan KJ, Ratnaike TE, Gruyter HL, Jaros E, Turnbull DM, Neurobiol Aging 2011
10. Kinetic and structural analysis of the early oxidation products of dopamine: analysis of the interactions with alphasynuclein. Bisaglia M, Mammi S, Bubacco L, J Biol Chem 2007 282 15597 15605 10.1074/jbc.M610893200 17395592 (Pubitemid 47093273)
11. The comparative biology of neuromelanin and lipofuscin in the human brain. Double KL, Dedov VN, Fedorow H, Kettle E, Halliday GM, Garner B, Brunk UT, Cell Mol Life Sci 2008 65 1669 1682 10.1007/s00018-008-7581-9 18278576
12. Modifications of the iron-neuromelanin system in Parkinson's disease. Fasano M, Bergamasco B, Lopiano L, J Neurochem 2006 96 909 916 10.1111/j.1471-4159.2005.03638.x 16417570
13. Neuromelanin activates microglia and induces degeneration of dopaminergic neurons: implications for progression of Parkinson's disease. Zhang W, Phillips K, Wielgus AR, Liu J, Albertini A, Zucca FA, Faust R, Qian SY, Miller DS, Chignell CF, Wilson B, Jackson-Lewis V, Przedborski S, Joset D, Loike J, Hong JS, Sulzer D, Zecca L, Neurotox Res 2011 19 63 72 10.1007/s12640-009-9140-z 19957214
14. Neuromelanin can protect against iron-mediated oxidative damage in system modeling iron overload of brain aging and Parkinson's disease. Zecca L, Casella L, Albertini A, Bellei C, Zucca FA, Engelen M, Zadlo A, Szewczyk G, Zareba M, Sarna T, J Neurochem 2008 106 1866 1875 18624918
15. Neuromelanin and its interaction with iron as a potential risk factor for dopaminergic neurodegeneration underlying Parkinson's disease. Gerlach M, Double KL, Ben-Shachar D, Zecca L, Youdim MB, Riederer P, Neurotox Res 2003 5 35 44 10.1007/BF03033371 12832223
16. Is the vulnerability of neurons in the substantia nigra of patients with Parkinson's disease related to their neuromelanin content? Kastner A, Hirsch EC, Lejeune O, Javoy-Agid F, Rascol O, Agid Y, J Neurochem 1992 59 1080 1089 10.1111/j.1471-4159.1992.tb08350.x 1494900
17. Alpha-synuclein redistributes to neuromelanin lipid in the substantia nigra early in Parkinson's disease. Halliday GM, Ophof A, Broe M, Jensen PH, Kettle E, Fedorow H, Cartwright MI, Griffiths FM, Shepherd CE, Double KL, Brain 2005 128 2654 2664 10.1093/brain/awh584 16000336 (Pubitemid 41552949)
18. Neuromelanin in human dopamine neurons: comparison with peripheral melanins and relevance to Parkinson's disease. Fedorow H, Tribl F, Halliday G, Gerlach M, Riederer P, Double KL, Prog Neurobiol 2005 75 109 124 10.1016/j.pneurobio.2005.02.001 15784302 (Pubitemid 40387414)
19. Individual dopaminergic neurons show raised iron levels in Parkinson disease. Oakley AE, Collingwood JF, Dobson J, Love G, Perrott HR, Edwardson JA, Elstner M, Morris CM, Neurology 2007 68 1820 1825 10.1212/01.wnl.0000262033. 01945.9a 17515544 (Pubitemid 46791395)
20. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Sulzer D, Trends Neurosci 2007 30 244 250 10.1016/j.tins.2007.03.009 17418429 (Pubitemid 46667168)
21. Staging of brain pathology related to sporadic Parkinson's disease. Braak H, Del Tredici K, Rub U, de Vos RA, Jansen Steur EN, Braak E, Neurobiol Aging 2003 24 197 211 10.1016/S0197-4580(02)00065-9 12498954 (Pubitemid 36007810)
22. Melanized dopaminergic neurons are differentially susceptible to degeneration in Parkinson's disease. Hirsch E, Graybiel AM, Agid YA, Nature 1988 334 345 348 10.1038/334345a0 2899295
23. Redox imbalance in Parkinson's disease. Chinta SJ, Andersen JK, Biochim Biophys Acta 2008 1780 1362 1367 10.1016/j.bbagen.2008.02.005 18358848
24. Oxidant stress evoked by pacemaking in dopaminergic neurons is attenuated by DJ-1. Guzman JN, Sanchez-Padilla J, Wokosin D, Kondapalli J, Ilijic E, Schumacker PT, Surmeier DJ, Nature 2010 468 696 700 10.1038/nature09536 21068725
25. Expression analysis of dopaminergic neurons in Parkinson's disease and aging links transcriptional dysregulation of energy metabolism to cell death. Elstner M, Morris CM, Heim K, Bender A, Mehta D, Jaros E, Klopstock T, Meitinger T, Turnbull DM, Prokisch H, Acta Neuropathol 2011 122 75 86 10.1007/s00401-011-0828-9 21541762
26. What causes mitochondrial DNA deletions in human cells? Krishnan KJ, Reeve AK, Samuels DC, Chinnery PF, Blackwood JK, Taylor RW, Wanrooij S, Spelbrink JN, Lightowlers RN, Turnbull DM, Nat Genet 2008 40 275 279 10.1038/ng.f.94 18305478 (Pubitemid 351311775)
27. Interplay between cytosolic dopamine, calcium, and alpha-synuclein causes selective death of substantia nigra neurons. Mosharov EV, Larsen KE, Kanter E, Phillips KA, Wilson K, Schmitz Y, Krantz DE, Kobayashi K, Edwards RH, Sulzer D, Neuron 2009 62 218 229 10.1016/j.neuron.2009.01.033 19409267
28. Glutathione Peroxidase 4 is associated with Neuromelanin in Substantia Nigra and Dystrophic Axons in Putamen of Parkinson's brain. Bellinger FP, Bellinger MT, Seale LA, Takemoto AS, Raman AV, Miki T, Manning- Bog AB, Berry MJ, White LR, Ross GW, Mol Neurodegener 2011 6 8 10.1186/1750-1326-6-8 21255396
29. Neuromelanin selectively induces apoptosis in dopaminergic SH-SY5Y cells by deglutathionylation in mitochondria: involvement of the protein and melanin component. Naoi M, Maruyama W, Yi H, Yamaoka Y, Shamoto-Nagai M, Akao Y, Gerlach M, Tanaka M, Riederer P, J Neurochem 2008 105 2489 2500 10.1111/j.1471-4159. 2008.05329.x 18399961 (Pubitemid 351782270)
30. Differential effects of human neuromelanin and synthetic dopamine melanin on neuronal and glial cells. Li J, Scheller C, Koutsilieri E, Griffiths F, Beart PM, Mercer LD, Halliday G, Kettle E, Rowe D, Riederer P, Gerlach M, Rodriguez M, Double KL, J Neurochem 2005 95 599 608 10.1111/j.1471-4159.2005. 03404.x 16135091 (Pubitemid 41457528)
31. Evidence for specific phases in the development of human neuromelanin. Fedorow H, Halliday GM, Rickert CH, Gerlach M, Riederer P, Double KL, Neurobiol Aging 2006 27 506 512 10.1016/j.neurobiolaging.2005.02.015 15916835 (Pubitemid 43185337)
32. Correspondence of melanin-pigmented neurons in human brain with A1-A14 catecholamine cell groups. Saper CB, Petito CK, Brain 1982 105 87 101 10.1093/brain/105.1.87 7066676 (Pubitemid 12001380)
33. Tyrosine hydroxylase and methionine-enkephalin in the human mesencephalon. Immunocytochemical localization and relationships. Gaspar P, Berger B, Gay M, Hamon M, Cesselin F, Vigny A, Javoy-Agid F, Agid Y, J Neurol Sci 1983 58 247 267 10.1016/0022-510X(83)90221-6 6131945 (Pubitemid 13185248)
34. Ageing and Parkinson's disease: substantia nigra regional selectivity. Fearnley JM, Lees AJ, Brain 1991 114 Pt 5 2283 2301 1933245
35. Neuronal loss is greater in the locus coeruleus than nucleus basalis and substantia nigra in Alzheimer and Parkinson diseases. Zarow C, Lyness SA, Mortimer JA, Chui HC, Arch Neurol 2003 60 337 341 10.1001/archneur.60.3.337 12633144 (Pubitemid 36314358)
36. Specific A10 dopaminergic nuclei in the midbrain degenerate in Parkinson's disease. McRitchie DA, Cartwright HR, Halliday GM, Exp Neurol 1997 144 202 213 10.1006/exnr.1997.6418 9126172 (Pubitemid 27149624)
37. The substantia nigra of the human brain. II. Patterns of loss of dopamine-containing neurons in Parkinson's disease. Damier P, Hirsch EC, Agid Y, Graybiel AM, Brain 1999 122 Pt 8 1437 1448 10430830 (Pubitemid 29374122)
38. Anatomy, pigmentation, ventral and dorsal subpopulations of the substantia nigra, and differential cell death in Parkinson's disease. Gibb WR, Lees AJ, J Neurol Neurosurg Psychiatry 1991 54 388 396 10.1136/jnnp.54.5.388 1865199
39. Parkinsonism, premature menopause, and mitochondrial DNA polymerase gamma mutations: clinical and molecular genetic study. Luoma P, Melberg A, Rinne JO, Kaukonen JA, Nupponen NN, Chalmers RM, Oldfors A, Rautakorpi I, Peltonen L, Majamaa K, Somer H, Suomalainen A, Lancet 2004 364 875 882 10.1016/S0140- 6736(04)16983-3 15351195 (Pubitemid 39221065)
40. Nature of mitochondrial DNA deletions in substantia nigra neurons. Reeve AK, Krishnan KJ, Elson JL, Morris CM, Bender A, Lightowlers RN, Turnbull DM, Am J Hum Genet 2008 82 228 235 10.1016/j.ajhg.2007.09.018 18179904 (Pubitemid 351726092)
41. Increase expression of alpha-synuclein in aged human brain associated with neuromelanin accumulation. Xuan Q, Xu SL, Lu DH, Yu S, Zhou M, Ueda K, Cui YQ, Zhang BY, Chan P, J Neural Transm 2011 118 1575 1583 10.1007/s00702-011- 0636-3 21461961
42. Diagnosis and management of dementia with Lewy bodies: third report of the DLB Consortium. McKeith IG, Dickson DW, Lowe J, Emre M, O'Brien JT, Feldman H, Cummings J, Duda JE, Lippa C, Perry EK, Aarsland D, Arai H, Ballard CG, Boeve B, Burn DJ, Costa D, Del Ser T, Dubois B, Galasko D, Gauthier S, Goetz CG, Gomez-Tortosa E, Halliday G, Hansen LA, Hardy J, Iwatsubo T, Kalaria RN, Kaufer D, Kenny RA, Korczyn A, et al. Neurology 2005 65 1863 1872 10.1212/01.wnl. 0000187889.17253.b1 16237129 (Pubitemid 43970103)
43. A multiplex real-time PCR method to detect and quantify mitochondrial DNA deletions in individual cells. Krishnan KJ, Bender A, Taylor RW, Turnbull DM, Anal Biochem 2007 370 127 129 10.1016/j.ab.2007.06.024 17662684 (Pubitemid 47404486)